1
Total investments
1
Early stage
0
Mid stage
0
Late stage
1y
Years active
Portfolio
1 investments · sorted by recency
All investments
Early stage
Mid stage
Late stage
Investor and helper
Feb 2025
FloBiotech is an early stage biotech company using advanced human brain cell models to develop disease-modifying therapeutic and diagnostic candidates to cure Alzheimer’s disease (AD). Our proprietary cell models (FloCells) will accelerate the search for and creation of effective treatments to transform Alzheimers drug discovery and development (and other Tauopathies). The powerhouse team brought together at FloBiotech has the expertise, the vision, and the revolutionary technology to deliver transformative results and save the lives of the people we love.
Experience · 2 entries
All (2)
Investments (1)
2025
Investor and helper
Feb 2025
FloBiotech is an early stage biotech company using advanced human brain cell models to develop disease-modifying therapeutic and diagnostic candidates to cure Alzheimer’s disease (AD). Our proprietary cell models (FloCells) will accelerate the search for and creation of effective treatments to transform Alzheimers drug discovery and development (and other Tauopathies). The powerhouse team brought together at FloBiotech has the expertise, the vision, and the revolutionary technology to deliver transformative results and save the lives of the people we love.
2016
Vice President, Head of Global Supply Chain Logistics and CDMO Partnerships
Sep 2016
Teva Pharmaceuticals has been developing and producing medicines to help improve people’s lives for more than a century. We are committed to being a global leader in generic and specialty medicines with a portfolio of 3,500 products in nearly every therapeutic area. Around 200 million people around the world take a Teva medicine every day. They are served by one of the largest and most complex supply chains in the pharmaceutical industry. Along with our established presence in generics, we have significant innovative research and operations supporting our growing portfolio of specialty and biopharmaceutical products. Learn more at www.tevapharm.com.
Please note that adverse effects for any of our products should be reported to: Safety.AE@teva.co.il
Product-specific questions should be directed to Teva or Teva Group subsidiaries in your country. Contact details and Tevas Pharmacovigilance Privacy Policy may be found here:
http://www.tevapharm.com/contact_us/